Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of three or more selected genes, e.g., a gene expression profile, from the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes of Table I, Table II, Table III, Table IV, Table V, Table VI or Table VII herein. Detection of changes in expression in the selected genes forming the gene expression profile from that of a reference gene expression profile are correlated with non-small cell lung cancer (NSCLC). One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile. Another composition for similar use contains a plurality of polynucleotides immobilized on a substrate, which probes hybridize to three or more gene expression products from genes in the gene expression profile. Still another composition involves detection of the protein expression products of genes from the gene expression profile.
1. A composition for evaluating the existence or progression of a lung cancer in a mammalian subject, said composition consisting essentially of polynucleotides or oligonucleotides, wherein each polynucleotide or oligonucleotide hybridizes to a gene, gene fragment, or gene transcript of a different marker in a mammalian blood sample, each marker being one of the markers in the combination consisting of:
(a) hepatitis B virus x associated protein (HBXAP or RSF1)
(b) dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2)
(c) YY1 transcription factor (YY1)
(d) chromosome 19 open reading frame 12, transcript variant 1 (C19orf12);
(e) thioesterase superfamily member 2 (THEM2)
(f) triple functional domain (PTPRF interacting) (TRIO)
(g) myeloid-associated differentiation marker, transcript variant 4 (MYADM)
(h) BAI1-associated protein 2 (BAIAP2)
(i) leucine zipper domain protein (FLJ22386 or ROGDI)
(j) DnaJ (Hsp40) homolog, subfamily B, member 14 (DNAJB14)
(k) brain and reproductive organ-expressed TNFRSF1A modulator (BRE),
(l) transmembrane protein 41A (TMEM41A)
(m) chromosome 9 open reading frame 64 (C9orf64)
(n) chromosome 20 open reading frame 55, transcript variant 1 (C20orf55 or FAM110A),
(o) pecanex-like 2 PCNXL2
(p) RE1-silencing transcription factor (REST)
(q) HSPC142 protein (HSPC142 or C19orf62)
(r) hypothetical protein BC015148 (LOC93081 or C13orf27)
(s) activating signal cointegrator 1 complex subunit 3 (ASCC3)
(t) solute carrier family 1, member 5 (SLC1A5)
(u) protein tyrosine phosphatase-like A domain containing 1 (PTPLAD1)
(v) MRE11meiotic recombination 11 homolog A (MRE11A)
(w) hypothetical protein or GTP-binding protein 10 (DKFZP686A10121 or GTPBP10)
(y) Soares fetal liver spleen 1NFLS cDNA clone IMAGp998K18127
(z) serpin peptidase inhibitor, clade I (pancpin), member 2 (SERPINI2),
(aa) cDNA FLJ44370 fis, clone TRACH3008902 or CAMP responsive element binding protein 1 (CREB1)
(bb) coiled-coil domain containing 53 (CCDC53)
(cc) ubiquitin specific peptidase 48 (USP48); and
(dd) zinc finger and SCAN domain containing 2, transcript variant 3 (ZSCAN2).
2. The composition according to claim 1 , which is a reagent comprising a substrate upon which said polynucleotides or oligonucleotides are immobilized.
3. The composition according to claim 1 , comprising a microarray, a microfluidics card, a chip or a chamber.
4. The composition according to claim 1 , which is a kit containing said polynucleotides or oligonucleotides.
5. The composition according to claim 4 , wherein said polynucleotides or oligonucleotides are each part of a primer-probe set, and said kit comprises both primer and probe, wherein each said primer-probe set amplifies a different gene or gene fragment.
6. The composition according to claim 1 , wherein one or more polynucleotide or oligonucleotide is associated with a detectable label.
7. The composition according to claim 1 , wherein the lung cancer is a non-small cell lung cancer of stage I or stage II.